Hyperphosphorylation and inactivation of CRMP2 has been detected in many neurological disorders, including Alzheimer’s and Parkinson’s disease, ALS, and chronic pain, and could thus be a promising drug target for the treatment of neurological diseases (Williamson et al., 2011; Moutal et al., 2019; Togashi et al., 2019). This evidence concerns the gene DPYSL2 and nervous system disorder.